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Antonio José Conde Moreno*, Carlos Ferrer Albiach, Rodrigo Muelas Soria, Verónica González Vidal,
Raquel García Gómez and María Albert AntequeraErratum
After the publication of this work [1], we noticed that an
incorrect version of Table two (Table 1 here) [1] was
published. The correct version of Table two (Table 1
here) is provided here.
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Table 1 Current Ongoing trials for Prostate Cancer Oligometastases in 2014 (www.clinicaltrials.gov)
Study ClinicalTrials.gov
Identifier
Phase Aim Arms Primary Objetives Secondary Objetives
Radiotherapy for Oligometastatic
Prostate Cancer
NCT01859221 2 Efficacy and safety in
patients with prymary
active or not
2: CR and HN Improvement in median
progression-free survival
in patients with metastatic
prostate cancer over historic
control rates in hormone
receptive and castration
resistant subgroups.
Improvement in overall survival
of patients with metastatic
prostate cancer.
University of Florida Treatment failure rates in patients
treated with stereotactic radiation
for metastatic prostate cancer.
after type of secondary outcome.
Quality of life in patients treated
with stereotactic radiation for
metastatic prostate cancer.
Stereotactic Radiosurgery in
Treating Patients With Metastatic
Breast Cancer, Non-Small Cell
Lung Cancer, or Prostate Cancer
NCT02206334 1 Safety Study 1 To determine the recommended
SBRT dose for each of the metastatic
locations being treated given the
individual and overlapping fields
when multiple metastases are treated
with SBRT in a national clinical trials
network setting.
I. To estimate rates of > = grade 3
(CTCAE 4.0) adverse events other
than a dose-limiting toxicity which
is possibly, probably, or definitely
related to treatment and which
occurs within 6 months from the
start of SBRT to multiple metastases.
NRG Oncology Foundation, Inc. II. To estimate the rates of long-term
adverse events occurring up to 2 years
from the end of SBRT.
Collaborator: NCI RTOG III. To explore the most appropriate
and clinically relevant technological
parameters to ensure quality and
effectiveness throughout radiation
therapy processes, including imaging,
simulation, patient immobilization,
target and critical structure definition,





NCT01558427 2 Defer the start of ADT 2: A. Active surveillance Androgen deprivation therapy
free survival.
Quality of life
University Hospital, Ghent B. Surgical or radiotherapy
treatment of metastases
Phase II Study of SBRT as
Treatment for Oligometastases
in Prostate Cancer
NCT02192788 2 Safety and Efficacy Study 1 Local and symptomatic control of














Table 1 Current Ongoing trials for Prostate Cancer Oligometastases in 2014 (www.clinicaltrials.gov) (Continued)
Collaborators: Chemotherapy-free survival and
overall survival.
SBRT-SG Analyze toxicities and quality of life




CR Castrate resistant, HR Hormone Receptive, NCI National Cancer Institut, RTOG Radiation Therapy Oncology Group, ADT androgen deprivation therapy
CTCAE 4.0: Common Terminology Criteria for Adverse Events SBRT-SG: Sterotactic Body Radiation Therapy Spanish Group
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